Two Draft Guidances Set Up FDA’s Plans To Gather Postmarket Data
Executive Summary
The guidance documents outline the statutory authority the US FDA has in requiring postmarket surveillance reports and studies, the real-world evidence it plans to ask for from sponsors, and administrative details that may be expected.
You may also be interested in...
Global Medtech Guidance Tracker: May 2021
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty guidance documents have been posted on the tracker since its last update.
International Regulators Agree On Foundations For Postmarket Clinical Studies
A new document from the IMDRF outlines the conditions for when postmarket clinical follow-up studies may be necessary, but underscores they have to conform to their local regulatory regimes.
Digital Health Roundup: Digital Therapeutics, Restoring Function, Deals, Investing And Lobbying
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.